Macroeconomic conditionspositive · 5 filings
“As a result of the inflationary environment, however, interest rates have increased, which has resulted in higher interest income rates than were previously realized.”10-Q · Aug 5, 2026 ↗
Kymera Therapeutics, Inc.
KYMR
Market read
Kymera Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Company-1.6% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- R&D rose to $119.5 million, including a $36.1 million increase tied to the STAT6 program and higher internal investment.
Invalidation: The isolated read changes if KYMR's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- R&D rose to $119.5 million, including a $36.1 million increase tied to the STAT6 program and higher internal investment.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods7
Price observations328
Usable filing statements131
Verified relationships7
Evidence supporting the case
- Macroeconomic conditions has repeated favorable evidence across 5 filings.
- Product pipeline and R&D has repeated favorable evidence across 5 filings.
Evidence challenging the case
- Latest annual revenue changed -16.7% year over year.
- Operating margin changed -335.3 percentage points in the latest annual period.
- Net margin changed -318.5 percentage points in the latest annual period.
- Diluted shares increased 12.6% in the latest annual period.
- Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
- EV/sales is 58% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
115.056m+48.4%12m+164.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$72.8M+114.0%$-2.09—
2022-12-31$46.8M-35.7%$-2.87+12.4%
2023-12-31$78.6M+67.8%$-2.52+8.2%
2024-12-31$47.1M-40.1%$-2.98+28.6%
2025-12-31$39.2M-16.7%$-3.69+12.6%
What management says matters
Persistent and emerging business drivers
Product pipeline and R&Dpositive · 5 filings
“The increase of $59.0 million was primarily due to a $36.1 million increase in costs related to our STAT6 program, a $15.6 million increase in personnel, equity-based compensation, occupancy, and other internal costs due to increased investment in employee ta…”10-Q · Aug 5, 2026 ↗
Restructuring and cost reductionsnegative · 3 filings
“The increase of $4.9 million was as a result of the occupancy of the 2021 Lease facility in February of 2024 and the corresponding exit of the 2019 Lease facility, resulting in an impairment charge of $4.9 million in the year ended December 31, 2024.”10-K · Feb 26, 2026 ↗
Legal and regulatory exposurepositive · 1 filings
“We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.”10-K · Feb 26, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 247.9× · EV/sales 238.8×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
115.05-1.6% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for KYMR. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for KYMR. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind KYMR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
GILDGilead Sciences, Inc.partnerFeb 24, 2026 ▾
“Entered into an exclusive option and license agreement with Kymera Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
KYMR is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for KYMR; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.